Obstetric pharmacogenomics
Journal of Basic and Clinical Physiology and Pharmacology · 25.09.2026 · 37 (5) · 355-360
DOI: 10.1515/jbcpp-2026-0183 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology, online erschienen am 11.08.2026. Verfasst von Ahizechukwu Chigoziem Eke. Beteiligte Einrichtung: Division of Maternal Fetal Medicine & Clinical Pharmacology, Department of Gynaecology and Obstetrics, Johns Hopkins University School of Medicine, B…. Hauptthemen laut MEDLINE: Pharmacogenetics, Obstetrics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Pregnancy profoundly alters drug disposition through dynamic physiologic adaptations affecting absorption, distribution, metabolism, and excretion. Although pharmacogenomics has transformed precision therapeutics across multiple medical specialties, its application during pregnancy remains limited because conventional pharmacogenomic models assume stable genotype-phenotype relationships that do not account for the temporal biologic changes of gestation. This mini-review proposes a conceptual framework for obstetric-pharmacogenomics in which maternal, placental, and fetal-genomes interact within a continuously evolving physiologic environment to shape drug exposure, therapeutic efficacy, and toxicity. Pregnancy-induced alterations in cytochrome P450 enzyme activity, drug transporters, placental metabolism, and immune regulation may amplify, attenuate, or fundamentally modify genetically determined drug responses, rendering static pharmacogenomic classifications insufficient. We discuss the clinical implications of this dynamic paradigm across several therapeutic areas, including antiretroviral therapy, maternal mental health, hypertensive disorders of pregnancy, and analgesia, and highlight the need for trimester-specific approaches to individualized drug therapy. We further examine current barriers to implementation, including the exclusion of pregnant women from pharmacogenomic research, limited longitudinal data, and ethical considerations surrounding fetal genetics. Integrating pharmacogenomics with physiologically based pharmacokinetic modeling and multi-omics technologies offers an opportunity to redefine precision-medicine in obstetrics and advance safer, more effective, and individualized pharmacotherapy for pregnant-women and their offspring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Maternal Fetal Medicine & Clinical Pharmacology, Department of Gynaecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Ahizechukwu Chigoziem Eke
Förderung
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Eke, A. C. (2026). Obstetric pharmacogenomics. Journal of Basic and Clinical Physiology and Pharmacology, 37(5), 355-360. https://doi.org/10.1515/jbcpp-2026-0183
Vancouver
Eke AC. Obstetric pharmacogenomics. Journal of Basic and Clinical Physiology and Pharmacology. 2026;37(5):355-360. doi:10.1515/jbcpp-2026-0183
BibTeX
@article{Eke2026,
author = {Eke, Ahizechukwu Chigoziem},
title = {Obstetric pharmacogenomics},
journal = {Journal of Basic and Clinical Physiology and Pharmacology},
year = {2026},
volume = {37},
number = {5},
pages = {355--360},
doi = {10.1515/jbcpp-2026-0183}
}
EUVIMED